How has avalglucosidase alfa impacted the treatment paradigm for both infantile-onset and late-onset Pompe disease in your experience?

What challenges do clinicians face in monitoring in disease progrission and response to therapy?

What factors influence your decision to switch a patient from alglucosidase alfa to avalglucosidase alfa?

Have you observed any significant differences in treatment outcomes between these two therapies in your local practice?